The present invention provides compounds, compositions thereof, and methods of using the same.
本发明提供了化合物、其组合物以及使用这些化合物的方法。
N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
申请人:Griffith David A.
公开号:US20120108619A1
公开(公告)日:2012-05-03
The invention provides a compound of Formula (I)
or a pharmaceutically acceptable salt thereof; wherein
G is
R
1
, R
2
and R
3
are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS
申请人:Ikaria Inc.
公开号:US20180066298A1
公开(公告)日:2018-03-08
Provided herein are compositions and methods for generating polypeptides using non-natural amino acids (nnAAs) and genetic machinery, wherein the modified polypeptides, such as therapeutic polypeptides, bind to albumin, such as serum albumin. Methods of substituting a non-natural amino acid in a first polypeptide to obtain a modified polypeptide, the nnAA in some instances comprising an albumin targeting group, are disclosed, as are methods for making populations of such modified polypeptides. A therapeutic polypeptide, interleukin-1 receptor antagonist (IL-1RA) is exemplified using the disclosed methods.
The present invention relates to compounds that inhibit of a5
b
1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5
b
1 and also that exhibit appropriate selectivity profile(s) against other integrins.
Polymyxin Derivates Useful As Antibacterial Agents
申请人:Magee Thomas Victor
公开号:US20120316105A1
公开(公告)日:2012-12-13
The present invention provides a new class of polymyxin derivates useful for treating bacterial infections, especially Gram-negative infections, that have reduced renal cytotoxicity.